

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

DE FLORA, et al.

Serial Number: 09/125,022

Filed: November 24, 1998

For: PHARMACEUTICAL COMPOSITION ENABLING TO INHIBIT CANCER
METASTASIS FORMATION CONTAINING N-ACETYL-CYSTEINE AND
DOXORUBICIN



Atty. Dck No. 108903-08035

Group Art Unit: 1623

Examiner: G. Kunz

OWENS

RESPONSE UNDER 37 CFR 1.116

Commissioner for Patents

Box AF

Washington, D.C. 20231

December 22, 2000

Sir:

In response to the Office Action dated September 26, 2000, please amend the
above-identified application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

13. (Once Amended) A method for inhibiting cancer metastasis formation in a
patient in need thereof, the method comprising administering to the patient [a cancer
metastasis formation inhibiting effective amount of] N-acetyl-cysteine and doxorubicin
together in a synergistic mixture or individually in amounts and within such a period as to
act synergistically together to produce a cancer metastasis formation inhibiting effect.